BIOMAT Database Logo BIOMAT Database Logo

Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. 1996

P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

The p38 mitogen-activated protein (MAP) kinase defines a subgroup of the mammalian MAP kinases that are induced in response to lipopolysaccharide, hyperosmolarity, and interleukin 1. p38 MAP kinase appears to play a role in regulating inflammatory responses, including cytokine secretion and apoptosis. Here we show that diverse classes of DNA-damaging agents such as cisplatinum, 1-beta-D-arabinofuranosylcytosine, UV light, ionizing radiation, and methyl methanesulfonate activate p38 MAP kinase. We also demonstrate that cells deficient in c-Abl fail to activate p38 MAP kinase after treatment with cisplatinum and 1-beta-D-arabinofuranosylcytosine but not after exposure to UV and methyl methanesulfonate. Reconstitution of c-Abl in the Abl-/- cells restores that response. Similar results were obtained for induction of the Jun-NH2-kinase/stress-activated protein kinase. These findings indicate that p38 MAP and Jun-NH2-kinase/stress-activated protein kinases are differentially regulated in response to different classes of DNA-damaging agents.

UI MeSH Term Description Entries
D008741 Methyl Methanesulfonate An alkylating agent in cancer therapy that may also act as a mutagen by interfering with and causing damage to DNA. Methylmethane Sulfonate,Dimethylsulfonate,Mesilate, Methyl,Methyl Mesylate,Methyl Methylenesulfonate,Methylmesilate,Mesylate, Methyl,Methanesulfonate, Methyl,Methyl Mesilate
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014466 Ultraviolet Rays That portion of the electromagnetic spectrum immediately below the visible range and extending into the x-ray frequencies. The longer wavelengths (near-UV or biotic or vital rays) are necessary for the endogenous synthesis of vitamin D and are also called antirachitic rays; the shorter, ionizing wavelengths (far-UV or abiotic or extravital rays) are viricidal, bactericidal, mutagenic, and carcinogenic and are used as disinfectants. Actinic Rays,Black Light, Ultraviolet,UV Light,UV Radiation,Ultra-Violet Rays,Ultraviolet Light,Ultraviolet Radiation,Actinic Ray,Light, UV,Light, Ultraviolet,Radiation, UV,Radiation, Ultraviolet,Ray, Actinic,Ray, Ultra-Violet,Ray, Ultraviolet,Ultra Violet Rays,Ultra-Violet Ray,Ultraviolet Black Light,Ultraviolet Black Lights,Ultraviolet Radiations,Ultraviolet Ray
D016315 Proto-Oncogene Proteins c-abl Non-receptor tyrosine kinases encoded by the C-ABL GENES. They are distributed in both the cytoplasm and the nucleus. c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation. abl Proto-Oncogene Proteins,c-abl Proteins,Proto-Oncogene Proteins abl,abl Proto-Oncogene Products,Products, abl Proto-Oncogene,Proteins abl, Proto-Oncogene,Proto Oncogene Proteins abl,Proto Oncogene Proteins c abl,Proto-Oncogene Products, abl,Proto-Oncogene Proteins, abl,abl Proto Oncogene Products,abl Proto Oncogene Proteins,abl, Proto-Oncogene Proteins,c abl Proteins,c-abl, Proto-Oncogene Proteins

Related Publications

P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Antigen activation of mitogen-activated protein kinase in mast cells through protein kinase C-dependent and independent pathways.
May 1997, Journal of immunology (Baltimore, Md. : 1950),
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Uncoupling ligand-dependent and -independent mechanisms for mitogen-activated protein kinase activation by the murine Ron receptor tyrosine kinase.
October 2005, The Journal of biological chemistry,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism.
April 1999, The Journal of biological chemistry,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
RGS16 attenuates galphaq-dependent p38 mitogen-activated protein kinase activation by platelet-activating factor.
January 1999, The Journal of biological chemistry,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Protein kinase C-dependent and -independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A2.
July 1994, The Journal of biological chemistry,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.
January 1999, Pharmacology & therapeutics,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
A novel protein kinase A-independent, beta-arrestin-1-dependent signaling pathway for p38 mitogen-activated protein kinase activation by beta2-adrenergic receptors.
October 2008, The Journal of biological chemistry,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Tryptanthrin prevents oxidative stress-mediated apoptosis through AMP-activated protein kinase-dependent p38 mitogen-activated protein kinase activation.
September 2017, Archives of pharmacal research,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms.
July 2010, Brain research,
P Pandey, and J Raingeaud, and M Kaneki, and R Weichselbaum, and R J Davis, and D Kufe, and S Kharbanda
Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria.
October 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Copied contents to your clipboard!